Endothelial dysfunction: How can one intervene at the beginning of the cardiovascular continuum?

Journal of Hypertension

Volumn 24, Issue SUPPL. 2, 2006, Pages

  Schmieder, Roland E ^a,b  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Angiotensin II receptor blockers; Angiotensin converting enzyme inhibitors; Diabetic nephropathy; Endothelial dysfunction; Ramipril; Telmisartan

Indexed keywords

ACETYLCHOLINE; ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; GLYCERYL TRINITRATE; HYDROCHLOROTHIAZIDE; IRBESARTAN; LOSARTAN; N(G) METHYLARGININE; NITRIC OXIDE; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; VALSARTAN;

ATHEROSCLEROSIS; CLINICAL TRIAL; CORONARY ARTERY; DIABETIC NEPHROPATHY; ENDOTHELIAL DYSFUNCTION; GLOMERULUS FILTRATION RATE; HEART PROTECTION; HUMAN; HYPERTENSION; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; MICROALBUMINURIA; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATHOGENESIS; PERIPHERAL CIRCULATION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; VASODILATATION;

EID: 33646415358     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.hjh.0000220101.57896.cd     Document Type: Review

References (39)

1. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Menzoian JO, Vita JA. Risk stratification for postoperative cardiovascular events via noninvasive assessment of endothelial function: a prospective study. Circulation 2002; 105:1567-1572.
2. Gokce N, Keaney JF Jr, Hunter LM, Watkins MT, Nedeljkovic ZS, Menzoian JO, et al. Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol 2003; 41:1769-1775.
3. Vita J, Keaney JJ. Endothelial function. A barometer for cardiovascular risk? Circulation 2002; 106:640-642.
4. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:233-246.
5. Weber MA. The 24-hour blood pressure pattern: does it have implications for morbidity and mortality? Am J Cardiol 2002; 89:27A-33A.
6. White WB. Relevance of blood pressure variation in the circadian onset of cardiovascular events. J Hypertens 2003; 21 (Suppl 6):S9-S15.
7. Otto ME, Svatikova A, Barretto RB, Santos S, Hoffmann M, Khandheria B, et al. Early morning attenuation of endothelial function in healthy humans. Circulation 2004; 109:2507-2510.
8. Deanfield J, Donald A, Ferri C, Giannattasio C, Halcox J, Halligan S, et al. Endothelial function and dysfunction. Part I: Methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23:7-17.
9. Corretti MC, Plotnick GD, Vogel RA. Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 1995; 268:H1397-H1404.
10. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005; 127:2254-2263.
11. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and interpreting the responses to drugs and mediators. Hypertension 1995; 25:918-923.
12. Drexler H, Hornig B. Importance of endothelial function in chronic heart failure. J Cardiovasc Pharmacol 1996; 27 (Suppl 2):S9-S12.
13. Perticone F, Ceravolo R, Pujia A, Ventura G, Iacopino S, Scozzafava A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001; 104:191-196.
14. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000; 101:1899-1906.
15. Zhou MS, Schulman IH, Raij L. Nitric oxide, angiotensin II, and hypertension. Semin Nephrol 2004; 24:366-378.
16. Burnier M. Angiotensin II type 1 receptor blockers. Circulation 2001; 103:904-912.
17. Higashi Y, Sasaki S, Nakagawa K, Ueda T, Yoshimizu A, Kurisu S, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J Am Coll Cardiol 2000; 35:284-291.
18. Schiffrin EL, Park JB, Intengan HD, Touyz RM. Correction of arterial structure and endothelial dysfunction in human essential hypertension by the angiotensin receptor antagonist losartan. Circulation 2000; 101:1653-1659.
19. 1 receptor blockade on endothelial function in essential hypertension. Am J Hypertens 2003; 16:123-128.
20. Marin J, Sanchez-Ferrer CF. Role of endothelium-formed nitric oxide on vascular responses. Gen Pharmacol 1990; 21:575-587.
21. Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28:149-167.
22. Svolis K, Svolis A, Lemboussi D, Loukopoulou P, Patronis A, Bakopoulos C, Stellas L. Telmisartan, an angiotensin II type 1 receptor blocker, improves endothelial function in essential untreated hypertensive patients. J Hypertens 2004; 22:194.
23. Petrovic J, Popovic Z, Petrovic D, Djuric D. Telmisartan - influence on endothelial dysfunction in hypertensive patients. J Renin Angiotensin Aldosterone Syst 2000; 1:74.
24. Joannides R, Bellien J, Iacob M, Eltchaninoff H, Ezzaher A, Bourkaib R, et al. Effect of acute angiotensin II type 1 receptor blockade on conduct arteries flow-dependent dilatation before and after NO-synthase inhibition. J Hypertens 2003; 21 (Suppl 4):S52.
25. Asmar R, Gosse P, Topouchian J, N'tela G, Dudley A, Shepherd GL. Effects of telmisartan on arterial stiffness in Type 2 diabetes patients with essential hypertension. J Renin Angiotensin Aldosterone Syst 2002; 3: 176-180.
26. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, Van Veldhuisen DJ, et al. Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population. Circulation 2002; 106:1777-1782.
27. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med 2004; 351:1285-1295.
28. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, et al. Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 2003; 108:2154-2169.
29. Dalla VM, Sacerdoti D, Bombonato G, Fioretto P, Finucci G, Saller A, et al. Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes. Eur J Endocrinol 2002; 146:687-694.
30. Delles C, Jacobi J, Schlaich MP, John S, Schmieder RE. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 2002; 15:3-9.
31. Delles C, Klingbeil AU, Schneider MP, Handrock R, Weidinger G, Schmieder RE. Direct comparison of the effects of valsartan and amlodipine on renal hemodynamics in human essential hypertension. Am J Hypertens 2003; 16:1030-1035.
32. Delles C, Schmieder RE. Renal endothelial effects of antihypertensive therapy. Curr Opin Nephrol Hypertens 2004; 13:489-493.
33. Higashi Y, Oshima T, Ozono R, Matsuura H, Kajiyama G. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension 1997; 30:252-258.
34. Weber M. The telmisartan Programme of Research tO show Telmisartan End-organ proteCTION (PROTECTION) programme. J Hypertens 2003; 21 (Suppl 6):S37-S46.
35. Schmieder RE, Delles C, Mimran A, Fauvel JP, Ruilope L. Effects of telmisartan versus ramipril on endothelium function of the renal vasculature in type 2 diabetes. J Hypertens 2005; 23 (Suppl 2):S147.
36. Parving H-H, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
37. Barnett AH, Bain SC, Bouter P, Karlberg BE, Madsbad S, Jervell J, et al. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 2004; 351:1952-1961.
38. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al., for the RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
39. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.